Right4Paws, a Coimbatore-based premium pet nutrition brand, has raised ₹14 crore in a Series A funding round from a group of high-net-worth individuals.
The funds raised will be used to expand its manufacturing infrastructure, scale production capacity and strengthen internal capabilities. The company also plans to onboard specialised talent, introduce new product categories across functional and life-stage nutrition, and expand its distribution footprint across Indian markets, while building a strong foundation for global exports.
Founded in 2020 by Dhanu Roy and Sameer Achan, Right4Paws is a Coimbatore-based premium pet nutrition brand owned by a pet care company, Pet Prakalp India. Pet Prakalp India operates as the research, innovation and manufacturing backbone of the business, while Right4Paws functions as its consumer-facing brand.
Right4Paws focuses on species-appropriate, whole-food-based nutrition developed through scientific validation. Products are designed with a health-first philosophy, prioritising digestive system of the species, nutrient absorption and long-term wellness.
At the core of this differentiation is Right4Paws’ patent-awaited proprietary Multi Factor Controlled Dehydration (MFCD) technology, which is designed to preserve ingredients’ nutrient integrity, bioavailability and natural characteristics.
Dhanu Roy, Founder & Director of Right4Paws, said, “This fundraise marks a major milestone in our mission to elevate pet nutrition standards in India. At Right4Paws, we combine the benefits of species-appropriate whole foods with the convenience of modern dry nutrition. Our science-led formulations led by veterinary nutritionists in UK and supported by years of R&D. The products are designed with whole foods around the digestive system of the pet, which delivers better health that eventually leads to longevity. Right4Paws has a vision to emerge as a trusted global natural pet food brand from India.”
Sameer Achan, Co-founder & Director of Right4Paws, said, “The strong investor confidence we have received reflects growing recognition of our differentiated philosophy, proprietary technology, go-to-market approach and long-term vision. This Series A funding gives us the foundation to expand rapidly, enter new product categories and prepare for international markets, while staying true to our focus on transparency, research-driven innovation and real health outcomes for pets.”
